Title | Minimal Residual Disease in Melanoma [electronic resource] : Biology, Detection and Clinical Relevance / edited by Uwe Reinhold, Wolfgang Tilgen |
---|---|
Imprint | Berlin, Heidelberg : Springer Berlin Heidelberg, 2001 |
Connect to | http://dx.doi.org/10.1007/978-3-642-59537-0 |
Descript | XII, 268 p. online resource |
I Biology of Micrometastases and Advances in Methods for Detection -- The Biology of Melanoma Micrometastases -- Disseminated Tumor Cells: Diagnosis, Prognostic Relevance, and Phenotyping -- Nested Quantitative Real Time PCR for Detection of Occult Tumor Cells -- Detection of Micrometastasis Through Tissue-Specific Gene Expression: Its Promise and Problems -- Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Patients -- Rapid Enrichment and Detection of Melanoma Cells from PBMC by a New Assay Combining Immunomagnetic Cell Sorting and Immunocytochemical Staining -- II. Detection of Residual Melanoma Cells in the Peripheral Blood and Bone Marrow -- Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Detection of Melanoma-Related Transcripts in the Peripheral Blood and Bone Marrow of Patients with Malignant Melanoma. What Have We Learned? -- The Clinical Utility of Multimarker RT-PCR in the Detection of Occult Metastasis in Patients with Melanoma -- Polymerase Chain Reaction in the Detection of Circulating Tumour Cells in Peripheral Blood of Melanoma Patients -- Facts and Pitfalls in the Detection of Tyrosinase mRNA in the Blood of Melanoma Patients by RT-PCR -- Morphologically Intact Melanoma Cells May Be Detected in Peripheral Blood of Melanoma Patients -- Prognosis of Metastatic Melanoma: No Correlation of Tyrosinase mRNA in Bone Marrow and Survival Time -- III. Detection of Minimal Residual Disease in Sentinel Nodes -- The Predictive Value of the Sentinel Lymph Node in Malignant Melanomas -- Detection of Micrometastasis in Sentinel Lymph Nodes of Patients with Primary Cutaneous Melanoma -- IV. Early Recognition and Monitoring by Serological Markers -- Monitoring Malignant Melanoma with the S-100B Tumour Marker -- Melanoma Inhibitory Activity (MIA), a Serological Marker of Malignant Melanoma -- Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients -- V. Clinical Relevance of Micrometastases Detection -- Molecular Tools in the Detection of Micrometastatic Cancer Cells โ Technical Aspects and Clinical Relevance -- The Clinical Relevance of Molecular Staging for Melanoma -- Clinical Significance of PCR-Positive mRNA Markers in Peripheral Blood and Regional Nodes of Malignant Melanoma Patients -- Decrease in Circulating Tumor Cells as an Early Marker of Therapy Effectiveness -- VI. Therapeutic Strategies Against Residual Melanoma Cells -- Utility of Tests for Circulating Melanoma Cells in Identifying Patients Who Develop Recurrent Melanoma -- Active Specific Immunotherapy of Malignant Melanoma and Peptide Mimics of the Human High-Molecular-Weight Melanoma-Associated Antigen -- Autologous Dendritic Cells for Treatment of Advanced Cancer โ An Update -- A Novel Strategy in the Elimination of Disseminated Melanoma Cells: Chimeric Receptors Endow T Cells with Tumor Specificity